Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01396187 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer